VISEN Pharmaceuticals (VISEN Pharma), a Cayman Islands-incorporated biotech firm listed in Hong Kong, disclosed a minor on-market share repurchase executed on 17 June 2026.

The company bought back 4,700 ordinary shares at prices between HKD 19.35 and HKD 19.67, for a total consideration of HKD 0.09 million. The volume-weighted average price was approximately HKD 19.42 per share.

Key post-transaction metrics: • Issued shares outstanding (excluding treasury shares) decreased to 113.77 million, representing a 0.004 % reduction from the preceding day’s balance. • Treasury shares rose to 153,100, keeping the total issued share count steady at 113.93 million. • Cumulative buybacks under the repurchase mandate approved on 27 June 2025 now stand at 153,100 shares, equivalent to 0.13 % of the 113.93 million shares authorized for repurchase (11.39 million). • In line with Hong Kong listing rules, VISEN Pharma is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.

The board confirms that the repurchase complied with all applicable listing rules and regulatory requirements.